A small number of batches of the insulin medication NovoMix 30 FlexPen and Penfill (Novo Nordisk) are to be recalled in the European Union, and the European Medicines Agency (EMA) is recommending that ...

Insulin Aspart (Novomix 30 Flexpen 100IU/ml) is a fast-acting form of the hormone insulin, prescribed for diabetes mellitus. It is used with other medium- or long-acting insulin products injected just ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor, diabetes education nurse, or pharmacist. Do not use if you have ever had an allergic ...

China's biggest solar firms shed nearly one-third of their workforces last year, company filings show, as one of the industries hand-picked by Beijing to drive economic growth grapples with falling ...

Diabetes patients in Europe were warned to be on alert after Novo Nordisk announced a recall of several batches of its NovoMix insulin. The recall affects batches of the prefilled insulin product ...

Insulin Aspart (Novomix-30 Penfill) is a fast-acting form of the hormone insulin, prescribed for diabetes mellitus. It is used with other medium- or long-acting insulin products injected just below ...

One of the affected products is a NovoMix 30 Flexpen The medicines watchdog, the MHRA, is urging people with diabetes to check their insulin pens. It says a manufacturing fault has led to some batches ...

Hi Doc! I was diagnosed with type 2 diabetes approx 1 year ago. I am currently using the Novomix Flexpen type insulin together with Rolab Metmorfin tablets. I am considering a change to Actraphane ...

New Delhi: Novo Nordisk India (www.novonordisk.com), the market leader in diabetes care and the insulin major, today launched two insulin analogues — NovoMix 30 and NovoRapid. NovoMix 30 is premixed ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Insulin Aspart: Key Patent, SPC, and Data Exclusivity Expiry - 44 Country Coverage" report to their offering. Pipeline ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Insulin Aspart - Comprehensive Patent Search" report to their offering. Eliminate unnecessary risk with the industry ...